鼻咽癌患者EBV潜伏膜蛋白1抗体血清学检测及临床意义

发布时间：2019-07-05 05:21

【摘要】：目的: 观察EB病毒(Epstein-Barr virus,EBV)潜伏膜蛋白1 (latent membrane protein 1, LMP-1)抗体在鼻咽癌(nasopharyngeal carcinoma,NPC)患者血清中的水平,探讨LMP-1抗体检测在NPC血清学诊断、预后判断及肿瘤靶向免疫治疗中的临床意义。 方法: 采用酶联免疫吸附试验(Enzyme-linked immunosorbent assay,ELISA)以及免疫印迹(Western blot)方法,以LMP1融合蛋白检测61例鼻咽癌患者、30例鼻咽增生性炎患者和55例正常人血清中LMP1抗体水平,比较三组血清抗体水平差异;分析鼻咽癌患者血清LMP1抗体水平与NPC临床、病理特征的关系。 结果: ELISA方法证实,鼻咽癌组LMP1抗体水平(0.618,[0.565-1.070])明显高于鼻咽增生性炎组( 0.567 , [0.534-0.632] )及正常组( 0.432 ,[0.375-0.476]),鼻咽增生性炎组LMP1抗体水平明显高于正常组,组间差异均有统计学意义(P 0.05)。鼻咽癌组LMP1抗体水平在鼻咽癌不同病理分级及有无淋巴结转移中均无统计学差异(P 0.05)。Western blot方法表明,鼻咽癌组LMP1抗体的表达较鼻咽增生性炎组及正常组均高。 结论: 研究结果提示,鼻咽癌组EB病毒LMP1抗体水平显著高于鼻咽增生性炎组及正常组,以LMP1融合蛋白进行LMP1抗体血清学检测可辅助EB病毒感染的筛查及鼻咽癌的临床诊断,EBV-LMP1融合蛋白亦可考虑作为肿瘤抗原标志物进行肿瘤靶向免疫治疗。
文内图片：
图片说明：鼻咽癌鼻内镜检查结果：鼻咽部新生物增生，，表面不平、坏死
[Abstract]:Aim: to observe the level of EB virus (Epstein-Barr virus,EBV) latent membrane protein 1 (LMP-1) antibody in serum of patients with nasopharyngeal carcinoma (nasopharyngeal carcinoma,NPC), and to explore the clinical significance of LMP-1 antibody detection in serological diagnosis, prognosis and tumor targeted immunotherapy of NPC. Methods: serum LMP1 antibody levels were detected by enzyme-linked immunosorbent assay (Enzyme-linked immunosorbent assay,ELISA) and immunoblotting (Western blot) in 61 patients with nasopharyngeal carcinoma, 30 patients with nasopharyngeal hyperplasia and 55 normal controls, and the relationship between serum LMP1 antibody levels and clinical and pathological features of NPC in patients with nasopharyngeal carcinoma was analyzed. Results: ELISA method confirmed that the level of LMP1 antibody in nasopharyngeal carcinoma group (0.618, [0.565 鈮

本文编号：2510272